Loading provider…
Loading provider…
Hematology & Oncology Physician in Chattanooga, TN
NPI: 1134485410Primary Employer
Tennessee Oncology - Nashville St Thomas Midtown
tnoncology.com
HQ Phone
Mobile
Get MD Wade's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTN State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 125 | 291 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 89 | 288 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 75 | 75 |
| 4 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 18 | 32 |
| 5 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 12 | 12 |
Immune checkpoint pathways in non-small cell lung cancer.
Authors: Young Cha, Nisha Mohindra, Victoria Villaflor, Francis Giles
Journal: Ann Transl Med
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer.
Authors: Lova Sun, Jorge Nieva, Vamsidhar Velcheti, Joshua Reuss, David Camidge, Vincent Lam, Charu Aggarwal
Journal: Pharmacoepidemiol Drug Saf
Lead Sponsor: EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Intervention / Treatment: RADIATION: Radiotherapy, DRUG: Avelumab, DRUG: M3814
Lead Sponsor: EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Intervention / Treatment: DRUG: Pembrolizumab, DRUG: M7824
Lead Sponsor: Nitto BioPharma, Inc.
Intervention / Treatment: DRUG: NBF-006